WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, June 18, 2015

Inhaled Levodopa May Bridge Parkinson's 'Off' Periods

June 16,2015


SAN DIEGO -- An inhaled formulation of levodopa reduced breakthrough motor symptoms in Parkinson's disease patients during periods when their oral levodopa therapy had worn off, researchers reported here.

In a phase IIb study, patients on the investigational drug CVT-301 had a significant reduction in Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores over 4 weeks compared with placebo, Robert Hauser, MD, of the University of South Florida Medical Center in Tampa, and colleagues reported in a poster at the Movement Disorders Society meeting here.

"It can serve an unmet need," Hauser told MedPage Today. "If it proves safe and effective in phase III trials, it has the potential to be helpful."
"Off" episodes involve re-emergence of motor symptoms such as an impaired ability to move, muscle stiffness, and tremor; these occur because the effectiveness of oral levodopa wanes before the next dose can safely be given. Current therapies for these episodes, which affect up to half of all patients on levodopa, are limited, the researchers said.

Since levodopa is the most effective oral treatment for Parkinson's symptoms, the ability to bridge those periods between doses could be useful, Hauser said.
For the study, the researchers randomized 86 patients with Parkinson's disease to either the investigational inhaled product or to placebo during a 4-week period. For the first 2 weeks, patients took a 35-mg dose, and for the last 2 weeks they took the 50-mg dose.

All patients were on levodopa therapy, and their mean intake was 770 mg/day, with an average "off" time of 6 hours per day.
The primary outcome was change in scores on the UPDRS Part III during "off" periods.
On average, patients used the "rescue" levodopa or placebo about two times per day.
Hauser and colleagues found that the drug significantly improved UPDRS Part III scores at all time points between 10 and 60 minutes after administration compared with placebo (P<0.05).
By the end of the 4-week study, mean change in UPDRS Part III scores were significantly better for drug patients, for both doses:

       35 mg: -9.9 versus -5.3, P=0.007
       50 mg: -10 versus -3.1, P<0.001

Patients also reported reductions in "off" time -- by 1.1 hours/day with the 35-mg dose, and by a significant 1.6 hours/day with the 50-mg dose.
There were more adverse events in the drug group -- 47% versus 33% -- including dizziness, cough, nausea, and anxiety, which could be tied to an excess of drug, but that would need further study, Hauser said.
They concluded that inhaled levodopa improves motor function as early as 10 minutes after administration, reduces "off" time, and appears to be safe and well tolerated.

Drugmaker Acorda Therapeutics is currently enrolling patients in a phase III trial of the drug.
Peter Jenner, MD, of King's College London, said in a statement that the novel inhaled formulation "appears to offer a further and novel route of administration of levodopa that can be used to treat 'off' periods."

"My immediate thought is that it will offer an alternative to rescue from 'off' periods currently achieved by subcutaneous injection of apomorphine," Jenner said. "A noninvasive form of rescue therapy will have utility and convenience for patients with Parkinson's disease experiencing sudden 'off' and improve their quality of life."


http://www.medpagetoday.com/MeetingCoverage/MDS/52166

Reviewed by Rebecca Farber, MD Corinne Goldsmith Dickinson Center for Multiple Sclerosis, The Mount Sinai Hospital, New York, NY 
LAST UPDATED 

No comments:

Post a Comment